 |
|
|
| |
Characterization of Changes in Lipoprotein Profiles of Patients With Nonalcoholic
Steatohepatitis Treated With the Acetyl-CoA Carboxylase Inhibitor GS-0976
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Parvez Mantry,1 Zeid Kayali,2 Mazen Noureddin,3 Peter Ruane,4 Bryan J. McColgan,5 Jacqueline Tarrant,5 Lulu Wang,5 Tuan Nguyen,5 Eliza Harting,5
C. Stephen Djedjos,5 Adrian S. Ray,5 Robert P. Myers,5 Michelle Lai,6 Michael Charlton,7 Eric J. Lawitz,8 Stephen A. Harrison,9 Rohit Loomba10
1The Liver Institute at Methodist Dallas, Dallas, Texas, USA; 2Inland Empire Liver Foundation, Rialto, California, USA; 3Cedars-Sinai Medical Center, Los Angeles, California, USA; 4Ruane Medical & Liver Health Institute, Los Angeles, California, USA; 5Gilead Sciences, Inc., Foster City, California, USA;
6Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA; 7University of Chicago, Chicago, Illinois, USA; 8Texas Liver Institute and UT Health San Antonio, Texas, USA; 9Pinnacle Clinical Research, San Antonio, Texas, USA; 10UC San Diego, La Jolla, California, USA
EASL: Proof-of-concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor (FXR) agonist (GS-9674) in NASH - (04/18/18)
AASLD: Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis (NASH) - (11/13/17)
AASLD: Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Significant Improvements in MRI-PDFF in a Phase 2, Randomized, Placebo-Controlled Trial of Patients with NASH - (10/28/17)
AASLD: Combination of ASK1 and ACC Inhibitors Increases Efficacy in Rodent Models of NASH - (11/13/17)
AASLD: Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamic Effects on de Novo Lipogenesis of the Acetyl-CoA Carboxylase Inhibitor GS-0976 in Healthy Volunteers - (11/13/17)
AASLD: A Liver-Targeted Acetyl-CoA Carboxylase Inhibitor Increases Fatty Acid Oxidation, Improves Mitochondrial Function, and Reduces Bile Acids and Oxidative Stress in a Murine Model of NASH - (11/13/17)
References
1. Loomba R, et al. AASLD 2017, abstr LB-9; 2. Goedeke L, et al. EASL 2018, abstr 450; 3. Kim CW, et al. Cell Metabol 2017;26:394-406; 4. Davidson M, et al. J Clin Lipidol 2011;5:338-67; 5. Cromwell W, et al. J Clin Lipidol 2007;1:583-92; 6. Mackey RH, et al. J Am Coll Cardiol 2012;60:508-16.
|
| |
|
|
|
|
|
